证券代码：600684 证券简称：珠江股份 编号：2025-042 广州珠江发展集团股份有限公司 关于向特定对象发行股票申请获得上海证券 交易所审核通过的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 广州珠江发展集团股份有限公司（以下简称"公司"）于 2025 年 7 月 24 日收 到上海证券交易所出具的《关于广州珠江发展集团股份有限公司向特定对象发行股 票的交易所审核意见》，具体审核意见如下： "广州珠江发展集团股份有限公司向特定对象发行股票申请符合发行条件、上 市条件和信息披露要求。本所将在收到你公司申请文件后提交中国证监会注册。" 公司本次向特定对象发行股票事项尚需获得中国证券监督管理委员会（以下简 称"中国证监会"）同意注册后方可实施，最终能否获得中国证监会作出同意注册 的决定及其时间尚存在不确定性。公司将根据该事项的进展情况，按照有关规定和 要求及时履行信息披露义务，敬请广大投资者注意投资风险。 特此公告。 广州珠江发展集团股份有限公司董事会 2025 年 7 月 25 日 ...

Group 1 - Leshan Electric achieved operating revenue of 1.623 billion yuan, a year-on-year increase of 1.94%, and a net profit of 7.9031 million yuan, a year-on-year decrease of 14.55% [1] - Zhimingda reported operating revenue of 295 million yuan, a year-on-year increase of 84.83%, and a net profit of 38.3 million yuan, a year-on-year increase of 2147.93% [2] - Dahu Co. reported operating revenue of 426 million yuan, a year-on-year decrease of 14.40%, and a net loss of 2.5716 million yuan, an improvement from a loss of 13.7824 million yuan in the same period last year [3] - Yubang Electric expects a net profit of 21.2 million to 25 million yuan, a year-on-year decrease of 35.47% to 45.28% [4] - Zhejiang Securities achieved operating revenue of 6.512 billion yuan, a year-on-year decrease of 18.60%, and a net profit of 1.149 billion yuan, a year-on-year increase of 46.54% [5] - Huashu Media reported operating revenue of 4.435 billion yuan, a year-on-year increase of 2.07%, and a net profit of 254 million yuan, a year-on-year increase of 4.63% [7] Group 2 - Sinopec reported oil and gas equivalent production of 262.81 million barrels, a year-on-year increase of 2%, and crude oil processing volume of 119.97 million tons, a year-on-year decrease of 5.3% [8] - Hengrui Medicine's subsidiary received approval for clinical trials of HRS8179, aimed at reducing brain edema after stroke [8] - Hengrui Medicine's subsidiary also received approval for clinical trials of HRS-1893, intended for treating heart failure with preserved ejection fraction [8] - Wanfu Co. announced a plan to reduce its stake by up to 2% through block trading [10] - Biological Co. received a warning letter from the Inner Mongolia Securities Regulatory Bureau for inaccuracies in financial reporting [11] - Zhujiang Co. reported a signed construction area of 47.1432 million square meters across 396 projects [13] Group 3 - Watson Bio received a patent for a peptide delivery system for RNA drugs [15] - Sanwei Chemical signed 31 new contracts worth 335 million yuan in the second quarter [17] - Shenzhou Cell's SCT640C injection received approval for clinical trials for rheumatoid arthritis [18] - Xinjiang Jiaojian reported new contracts worth 1.434 billion yuan in the second quarter [19] - Lais Information plans to use 550 million yuan of idle funds for cash management [21] - Zhongqi New Materials signed a mining rights transfer contract, increasing production capacity [22] Group 4 - Hengtong Optic-Electric won multiple marine energy projects worth 1.509 billion yuan [24] - China State Construction signed new contracts totaling 2.501 trillion yuan in the first half of the year [26] - David Medical's ventilator product registration application has been accepted [28] - Tianhai Defense's subsidiary signed a construction contract worth 16.224 million yuan [29] - Nantian Information plans to sign a procurement framework contract worth 58.27 million yuan with its controlling shareholder [31] - Baida Group announced a plan to reduce its stake by up to 3% [32] Group 5 - Jinli Permanent Magnet plans to issue $117.5 million in convertible bonds [34] - Haizheng Pharmaceutical's fumarate bedaquiline raw material drug application has been approved [36] - Huatai passed the advanced intelligent factory re-evaluation in Anhui Province [37] - Everbright Bank's shareholder increased its stake from 7.08% to 8% [40] - Supor reported total operating revenue of 11.478 billion yuan, a year-on-year increase of 4.68%, and a net profit of 940 million yuan, a year-on-year decrease of 0.07% [41] - Qianjin Pharmaceutical's subsidiaries received registration certificates for two drugs [42]

证券代码：600684 证券简称：珠江股份 编号：2025-041 广州珠江发展集团股份有限公司 2025 年第二季度经营情况简报 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 广州珠江发展集团股份有限公司（以下简称"公司"）截至 2025 年第二季 度的主要经营情况如下： 截至 2025 年第二季度末，公司（含广州珠江城市管理服务集团股份有限公 司、广州珠江体育文化发展股份有限公司等）在管住宅、公建及体育场馆项目 数量共计 396 个，签约建筑面积共计约 4,714.32 万平方米。其中，公司在管住 宅项目 143 个，建筑面积约 2,014.72 万平方米；公建项目 222 个，建筑面积约 2,369.53 万平方米；体育场馆项目 31 个，建筑面积约 330.07 万平方米（以上 合计数与各数直接相加之和在尾数上存在差异，为四舍五入导致）。 广州珠江发展集团股份有限公司董事会 2025 年第二季度，体育场馆新增赣州全民健身中心、广州芳村工人文化宫 游泳场，建筑面积约 37.40 万平方米。 2025 年 7 月 25 ...

证券代码：600684 证券简称：珠江股份 编号：2025-040 广州珠江发展集团股份有限公司 关于资金拆借的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 截至 2025 年 6 月 30 日，广州珠江发展集团股份有限公司（以下简称"公司"或 "珠江股份"）对外资金拆借投资余额 40,000.00 万元，其中对广州东湛房地产 开发有限公司（以下简称"东湛公司"）的债权投资余额为 33,500.00 万元，对 广州市盛唐房地产开发有限公司（以下简称"盛唐公司"）的债权投资余额为 6,500.00 万元。 公司对东湛公司的债权投资 33,500 万元已于 2021 年 6 月 25 日到期未获清偿。 公司已分别于 2020 年、2021 年、2022 年、2023 年、2024 年对东湛公司的债权 投资计提资产减值准备 14,441.31 万元、7,445.40 万元、8,539.64 万元、140.37 万元、148.78 万元；截至 2024 年末，累计计提资产减值准备 30,715.50 万元。 ...

Group 1 - The board of directors of Guangzhou Zhujiang Development Group Co., Ltd. held its seventh meeting on July 16, 2025, via communication, with all 8 directors present [1][2] - The board approved the compensation plan for internal directors and senior management for the year 2024, with a voting result of 7 in favor and 0 against [1][2] - The board also approved the appointment of Qiu Yongchuan as the head of the audit department, following the departure of Liang Jinghui due to work adjustments, with a unanimous vote of 8 in favor [2]

证券代码：600684 证券简称：珠江股份 编号：2025-039 广州珠江发展集团股份有限公司 第十一届董事会 2025 年第七次会议决议 公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 广州珠江发展集团股份有限公司（以下简称"公司"）第十一届董事会 2025 年第七次会议于 2025 年 7 月 11 日以办公软件或电子邮件方式发出会议通 知及材料汇编，会议于 2025 年 7 月 16 日以通讯方式召开。本次会议应出席董 事 8 人，实际出席董事 8 人，由公司董事长李超佐先生召集并主持。会议的召 集、召开和表决程序符合有关法律、行政法规、部门规章、规范性文件和《公 司章程》的规定，并形成了如下决议： 本议案已经公司第十一届董事会薪酬与考核委员会 2025 年第二次会议审议 通过。 二、审议通过《关于聘任审计部负责人的议案》 表决情况：同意 8 票，反对 0 票，弃权 0 票。 鉴于梁景辉因工作调整不再担任公司审计部负责人，根据《内部审计工作 制度》等相关规定，同意聘任丘咏川为公司审计部负责人。丘咏川简历如下： 丘 ...

[Current Period Performance Forecast](index=1&type=section&id=Item%201.%20Current%20Period%20Performance%20Forecast) The company anticipates a turnaround to profitability in the first half of 2025, with net profit attributable to shareholders projected between **RMB 15.5 million and RMB 22.5 million**, and non-recurring net profit between **RMB 7 million and RMB 10.5 million**, based on unaudited preliminary estimates Current Period Performance Forecast | Indicator | Estimated Amount (RMB) | | :--- | :--- | | Performance Forecast Period | January 1, 2025 to June 30, 2025 | | Net Profit Attributable to Shareholders | RMB 15.5 million to RMB 22.5 million | | Net Profit Attributable to Shareholders Excluding Non-Recurring Items | RMB 7 million to RMB 10.5 million | - The company explicitly states that this performance forecast is based on preliminary calculations and has not been audited by an accounting firm[2](index=2&type=chunk) [Prior Period Performance Review](index=1&type=section&id=Item%202.%20Prior%20Period%20Operating%20Performance%20and%20Financial%20Status) In the first half of 2024, the company reported a net loss attributable to shareholders of **RMB 6.2359 million**, while net profit excluding non-recurring items was **RMB 22.2589 million**, indicating core business profitability 2024 H1 Actual Performance | Indicator | 2024 H1 Actual Amount (RMB) | | :--- | :--- | | Total Profit | RMB 2.7370 million | | Net Profit Attributable to Shareholders | -RMB 6.2359 million | | Net Profit Attributable to Shareholders Excluding Non-Recurring Items | RMB 22.2589 million | | Earnings Per Share | -RMB 0.01 | [Analysis of Performance Change](index=1&type=section&id=Item%203.%20Primary%20Reasons%20for%20Current%20Period%20Pre-Profit) The turnaround to profitability is primarily driven by changes in non-recurring gains and losses, specifically the fair value increase of equity investments due to the A-share market recovery in H1 2025, contrasting with prior period losses from market decline, while core business profitability (non-recurring net profit) has declined year-over-year - The primary reason for the turnaround to profitability is the change in fair value of the company's equity investments, with gains from A-share market recovery in H1 2025 contrasting with losses from market decline in the prior period[5](index=5&type=chunk) Performance Comparison | Indicator | 2025 H1 (Estimated) | 2024 H1 (Actual) | Key Change | | :--- | :--- | :--- | :--- | | Net Profit Attributable to Parent | RMB 15.5-22.5 million | -RMB 6.2359 million | **Turnaround to Profit** (Impacted by non-recurring items) | | Net Profit Attributable to Parent Excluding Non-Recurring Items | RMB 7-10.5 million | RMB 22.2589 million | **Year-over-Year Decline** (Core business profitability weakened) | [Risk Warning](index=2&type=section&id=Item%204.%20Risk%20Warning) The company advises investors that the disclosed performance data are preliminary and unaudited, subject to potential differences from the final financial figures in the official 2025 semi-annual report, urging caution regarding investment risks - The announcement emphasizes that the forecast data are preliminary, and the final accurate financial figures will be based on the company's officially disclosed 2025 semi-annual report[6](index=6&type=chunk)

Group 1 - CITIC Construction Investment has received approval from the China Securities Regulatory Commission to issue perpetual subordinated bonds with a total face value of no more than 20 billion yuan [1] - Bluefocus Technology has received a loan commitment of up to 900 million yuan from CITIC Bank for stock repurchase [1] - Huaren Pharmaceutical's subsidiary has received approval for the listing of Bumetanide raw materials, which are used to treat severe heart failure and hypertension emergencies [3] Group 2 - Betta Pharmaceuticals has received approval for the listing of Enasidenib capsules in Macau, aimed at treating ALK-positive locally advanced or metastatic non-small cell lung cancer [4] - Juewei Food plans to use 110 million yuan of idle fundraising for cash management, with an expected annual yield of 1.00%-1.89% [6] - China Huadian has successfully completed the issuance of 1 billion yuan medium-term notes with a coupon rate of 1.95% [9] Group 3 - Fosun Pharma's subsidiary has received a GMP certificate from the Belgian Federal Agency for Medicines and Health Products for the production facilities of two monoclonal antibodies [11] - China Nuclear Engineering has signed a civil engineering contract for the Taishan Nuclear Power Units 3 and 4 [13] - Kanglongda has faced administrative regulatory measures from the Zhejiang Securities Regulatory Bureau due to the failure of performance commitment parties to fulfill compensation obligations [15] Group 4 - Gaoling Information has received three invention patent certificates in the second quarter, covering various technological fields [16] - Weimais plans to use 190 million yuan of excess fundraising to increase capital in its subsidiary for building a new energy vehicle powertrain production base [17] - Huazhong Technology has received a project designation notice from a leading eVTOL manufacturer for the development and supply of an intelligent cockpit multimedia display system [19] Group 5 - Madi Technology expects a net profit of 25 million to 27 million yuan for the first half of 2025, marking a turnaround from a loss in the previous year [19] - Dazhong Mining's subsidiary has obtained a mining license for the Zhouyoufang Iron Mine, increasing production capacity to 6.5 million tons per year [20] - Zhongguancun's subsidiary has had its application for the listing of Arolol hydrochloride tablets accepted by the National Medical Products Administration [21] Group 6 - Tianhong Co. has signed a property management contract worth 15 million yuan with a local company [22] - Dong'an Power has secured nine new market designation agreements in the second quarter, with a projected total sales volume of 1.5 million units [24] - Zhujiang Co. has appointed Zhao Kun as the new deputy general manager [25] Group 7 - Jinyi Industrial has won a bid for a project worth 335 million yuan from the China Railway Shanghai Bureau Group [26] - Kangchen Pharmaceutical has received a clinical trial notification for its innovative drug KC1086, aimed at treating advanced solid tumors [27] - Changhua Group has received a project designation notice from a new energy vehicle company, with an expected total sales amount of 970 million yuan [29] Group 8 - Lingxiao Pump Industry plans to use 60 million yuan of idle funds to purchase financial products [31] - Mould Technology has received a project designation for exterior parts from a well-known North American electric vehicle company, with an expected total sales of 1.236 billion yuan [34] - Fulongma has pre-bid for five sanitation service projects in June, with a total contract amount of 181 million yuan [35] Group 9 - Changchun High-tech plans to issue H-shares and list on the Hong Kong Stock Exchange [36] - *ST Yuancheng is under investigation by the CSRC for suspected false financial disclosures [37] - Beilu Pharmaceutical's subsidiary has received approval for the listing of Iopamidol raw materials [38] Group 10 - Zhejiang Liming's shareholder plans to reduce their stake by up to 2.93% [39] - Zhejiang Liming's actual controller has committed not to reduce their holdings within a year [40] - SAIC Motor reported a total vehicle sales of 2.0526 million units in the first half of 2025, a year-on-year increase of 12.35% [41] Group 11 - Xinhongcheng expects a net profit increase of 50%-70% for the first half of 2025 [42] - Xianhe Co. plans to invest 11 billion yuan in a bamboo pulp paper integrated project [42] - Great Wall Motors reported a total vehicle sales of 569,800 units in the first half of 2025, a year-on-year increase of 1.81% [43] Group 12 - Dongfeng Co. received a government subsidy of 10 million yuan [44] - Zhongke Environmental Protection has acquired two water environmental companies in Guangxi for a total of 353 million yuan [45] - Anji Food's H-share public offering is priced at 60 Hong Kong dollars per share [46]

广州珠江发展集团股份有限公司 关于聘任副总经理的公告 证券代码：600684 证券简称：珠江股份 编号：2025-037 赵坤先生简历如下： 赵坤，男，1984 年 6 月生，汉族，中共党员，研究生学历，硕士学位，体 育经纪人三级、体育经理人三级。2011 年 6 月参加工作，曾任深圳市盐田体育 中心办公室主任，济宁珠江体育文化发展有限公司市场开发部部门经理、高新 区体育馆项目总经理、总经理助理、常务副总经理，广州珠江体育文化发展股 份有限公司总经理助理、第二党支部书记、第三党支部书记、副总经理，现任 广州珠江体育文化发展股份有限公司常务副总经理，本公司党委委员。 截至目前，赵坤先生未持有公司股票，未受过中国证券监督管理委员会及 其他相关部门的处罚和上海证券交易所惩戒，不存在《中华人民共和国公司法》 等法律法规及其他有关规定不得担任上市公司董事、监事和高级管理人员的情 形。 特此公告。 广州珠江发展集团股份有限公司董事会 2025 年 7 月 3 日 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 2025 年 7 月 1 日 ...

证券代码：600684 证券简称：珠江股份 编号：2025-036 广州珠江发展集团股份有限公司 第十一届董事会 2025 年第六次会议决议 公告 根据战略规划实施情况及实际经营情况，以精简高效、有效运作为原则， 同意调整公司组织架构。原 14 个部门调整为 10 个部门，调整后的部门分别为： 综合管理部、财务部、法律合规部、党群工作部、审计部、纪委办公室、资本 运营部/董事会办公室、战略投资部、公共关系部、数字信息部。 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 广州珠江发展集团股份有限公司（以下简称"公司"）第十一届董事会 2025 年第六次会议于 2025 年 6 月 26 日以办公软件或电子邮件方式发出会议通 知及材料汇编，会议于 2025 年 7 月 1 日以通讯方式召开。本次会议应出席董事 8 人，实际出席董事 8 人，由公司董事长李超佐先生召集并主持。会议的召集、 召开和表决程序符合有关法律、行政法规、部门规章、规范性文件和《公司章 程》的规定，并形成了如下决议： 一、审议通过《关于聘任副总经理的议案》 表决 ...